Objective: To explore the prognostic importance and preoperative predictors of lymph node metastasis in an effort to guide surgical decision making in patients with pancreatic neuroendocrine tumors (PNETs). Background: PNETs are uncommon, and the natural history of the disease is not well described. As a result, there remains controversy regarding the optimal management of regional lymph nodes during resection of the primary tumor. Methods: A retrospective review of a prospectively maintained database of patients who underwent surgery for locoregional PNET between 1994 and 2012 was performed. Logistic regression was used to identify predictors of nodal metastasis. Overall survival and disease-free survival were calculated using Kaplan-Meier method. Results were expressed as P values and odds ratio estimates, with 95% confidence intervals. Results: One hundred thirty-six patients were identified, of whom 50 (38%) patients had nodal metastasis. The frequency of lymph node metastasis was higher for larger tumors [> 1.5 cm (odds ratio [OR] = 4.7)], tumors of the head as compared with body-tail of the pancreas (OR = 2.8), tumors with Ki-67 greater than 20% (OR = 6.7), and tumors with lymph vascular invasion (OR = 3.6) (P < 0.05). Median disease-free survival was lower for patients with nodal metastases (4.5 vs 14.6 years, P < 0.0001). Conclusions: Lymph node metastasis is predictive of poor outcomes in patients with PNETs. Preoperative variables are not able to reliably predict patients where the probability of lymph node involvement was less than 12%. These data support inclusion of regional lymphadenectomy in patients undergoing pancreatic resections for PNET.
clinical outcomes of PNETs vary greatly, and although the majority are relatively benign, slow growing, and noninfiltrative, a subset is aggressive, rapidly metastasizing, and locally invasive. PNETs can also be divided into functional and nonfunctional on the basis of hypersecretion of biologically active hormones, resulting in clinical syndromes. 4 The natural history of PNETs is consequently highly variable, with the majority having a more favorable outcome and longer overall survival (OS) after surgical resection than pancreatic adenocarcinoma. 5 Bilimoria et al 6 reported 5 and 10 years of OS after surgical resection of PNET as 59.3% and 37.7%, respectively. The mainstay of treatment for nonmetastatic PNETs is surgery. 7, 8 The often-indolent disease course and uncommon incidence of PNETs presents a considerable challenge to prospective study. Retrospective reviews with highly variable long-term follow-up have contributed to variable practice patterns. In addition, many studies have inadequate or inconsistent lymph node sampling whereas others lack consistent pathological evaluation. 9 As a result, the importance of lymph node metastasis on survival and recurrence remains uncertain. Some studies demonstrated the prognostic importance of nodal metastasis as a prognostic factor for PNET, 10, 11 whereas others failed to find any such association. 6, 12 Pancreatic resections are associated with significant morbidity, 13 and there is interest in minimizing the impact of surgery. Enucleation and central pancreatectomy in selected patients utilizing initially open and more recently with minimally invasive techniques have been reported. [14] [15] [16] These procedures have low morbidity and shorter hospital stay than standard pancreatectomy. [14] [15] [16] However, it remains difficult to predict which tumors are appropriate for enucleation, because we do not have a validated way to determine which tumors are unlikely to have metastasized. Prior studies reported controversial results regarding the predictors of nodal metastasis. 17, 18 As a result, the surgical approach and indications for lymph nodes dissection in PNET remain unclear.
In this retrospective review of a prospectively maintained institutional database, we determined which preoperative factors were associated with lymph nodes metastasis. We further determined associations between lymph node metastases and survival [disease-free survival (DFS) and OS]. Our goal was to attempt to identify a lowrisk group where regional lymphadenectomy could be eliminated and limited resection (enucleation, central pancreatectomy, etc) would be appropriate. Ninety-eight percent of the patients included in this study underwent regional lymph nodes sampling, placing us in a unique position to look at this question. %; perineural, lymphovascular invasion (LVI); surgical margin; and lymph node status were reviewed. In cases in which Ki-67 % was not reported, slides were cut, stained, and reviewed by a dedicated pancreatic pathologist. This study was approved by the institutional review board at Washington University in St Louis and by the human studies committee of the Siteman Cancer Center.
Tumor size was determined by measuring the maximum tumor diameter in the pathological specimen. Tumor locations were coded as either proximal (head) or distal (body-tail). A tumor was considered functional if the patient was symptomatic, with documented elevation of a hormone level and positive immunohistochemistry staining. Negative surgical margin (R0) was defined as macro-and microscopic absence of cancer cells at all resection margins on permanent section. Microscopic positive margin (R1) was defined as the microscopic presence of malignant cells smaller than 1 mm from any margin. Macroscopic positive margin (R2) was defined as presence of gross residual cancer as defined by the American Joint Committee on Cancer. 19 DFS was defined as the time from operation to the first disease recurrence. The date of recurrence was considered the first date of radiological evidence of disease recurrence. Patients who were alive and disease free were censored at the date of last contact. OS was considered to be the time from surgery to the time of death. Date of death was determined from the medical records and when not available from social security death index. Patients who were alive at the date of last contact were censored at that date. Disease status was categorized as died of disease, died of other cause, alive with disease, and no evidence of disease.
Continuous variables were expressed as median and range or mean and standard deviation. Univariate logistic regression was used to model node involvement (N stage > 0) to identify factors predictive of lymph node metastasis. Multivariate logistic regression models were created to assess whether any of the predictors of nodal metastasis were independent. To assess factors significantly affecting OS and DFS including lymph nodes metastasis, Kaplan-Meier models were created. Log-rank test was used to evaluate the significant difference. Multivariate Cox proportional hazard models were used to evaluate whether any of these factors were independent predictors of OS and DFS. The results were expressed as odds and hazard ratio estimates with 95% confidence intervals, and P-values were considered significant if 0.05 or less. Statistical analyses were performed and figures were generated using SAS version 9.3 (SAS Institute Inc, Cary, NC) for Linux and GraphPad Prism version 5 (GraphPad Software, Inc, San Diego, CA).
RESULTS
A total of 175 patients with primary PNET who underwent surgical resection between April 1, 1994 and October 1, 2012 were identified. Fourteen patients (8%) were excluded because of lack of data and insufficient follow-up. Twenty-five patients (14%) with distant metastasis (stage IV) at presentation were also excluded from the study. Thus, a total of 136 patients were included in the final analysis. Patient demographics and clinical characteristics can be found in Table 1 and tumors characteristics in Table 2 . The median age of the patients was 57.2 years (range: 24.3-83.9 years). The median follow-up was 4.9 years (range: 0.07-14.8 years). Lymph node resection was performed on 133 (98%) patients, 50 (37.6%) of whom were N1 whereas 83 (62.4%) were N0. The mean number ± SD of lymph node resected was 13.7 ± 11.5, and the number of positive lymph nodes in patients with N1 disease was 2.9 ± 2.5. There were no mortalities at 30 days and the overall complication rate was 39%. The most common complication was pancreatic leak at 7%. The majority of these were grade 1 leaks, requiring prolonged drainage after left pancreatectomy. The most severe complications were myocardial infarction (2 patients), stroke (1 patient), and bleed (3 patients).
FACTORS ASSOCIATED WITH LYMPH NODE METASTASIS
Tumor location, tumor size, LVI, and Ki-67 index were associated with lymph node metastasis. Two of these factors can be reliably identified preoperatively (tumor size and location). The others are measured from postoperative pathological evaluation (LVI and Ki-67) and cannot be reliably obtained from preoperative biopsies. Ethnicity, sex, age at operation, functional status of the tumor, multiple endocrine neoplasia type 1 (MEN-1), margin status, tumor grade, and presence of perineural infiltration were not found to be associated with increased or decreased risk of nodal metastasis.
Tumor Size
Tumor size was found to be associated with lymph node metastasis. Patients with tumor diameter greater than 1.5 cm were 4.7 times likely to have lymph node metastasis as compared with those with smaller tumor diameters [95% confidence interval (CI), 1.81-12.35; P = 0.002] ( Fig. 1 ). Tumor size was stratified into 4 different groups (≤1, 1.1-1.5, 1.6-2, and ≥2 cm; Fig. 2A ). The stratification showed that the proportion of patients with lymph node metastasis increased with larger tumor size. Interestingly, 2 (12%) of 17 patients with tumor size of 1 cm or smaller and 5 (13%) of 38 patients with tumor size of 1.5 cm or smaller had lymph nodes metastases.
Tumor Location
PNETs in the head of the pancreas were 2.8 times more likely to metastasize to the regional lymph nodes than tumors in the body and tail (95% CI, 1.3-5.8); P = 0.007) ( Fig. 1 ). Sixty-six patients had tumors in the head of the pancreas, 33 (50%) of whom were identified with nodal involvement (N1). Sixty-four patients had tumors in the body or tail of the pancreas, 17 (26.6%) of whom were identified with nodal metastases (N1) status and 47 (73.4%) had no documented nodal metastases (N0) (Fig. 2B ). The median number of lymph nodes examined in patients with tumors in the head and body-tail was 15 and 8, respectively (P = 0.0002). We evaluated whether the increase in nodal metastasis of tumor in the head is due to the location or to the fact that more lymph nodes were examined. A model adjusted to the number of nodes examined was created. Results showed that the odds ratio for N1 status of tumors in the head versus body-tail after adjustment of number of nodes is about 2.5 (P = 0.0006). Adding number of nodes examined did not significantly change the result. FIGURE 1. Logistic regression, probability of lymph node metastasis Ki-67 greater than 20%, LVI, tumor in the head versus body-tail, and size larger than 1.5 cm were found to be associated with increase in probability of lymph node metastasis (P = 0.008, 0.008, 0.004, and 0.002, respectively).
Lymphovascular Invasion
Patients with LVI were 3.6 times more likely to have nodal metastasis than patients without (95% CI, 1.5-8.6; P = 0.004) ( Fig. 1 ). LVI status was known for 97 patients, 36 of whom had LVI. Twenty-one patients (58.3%) with LVI had N1 whereas 15 (41.7%) had N0 (Fig. 2C ).
Tumor Proliferation
Groups were stratified into 3 groups with respect to Ki-67 percent: less than 2%, 2% to 20%, and more than 20%. Patients with Ki-67 greater than 20% were found to have lymph node metastasis 6.7 times more frequently than those with Ki-67 less than 2% (95% CI, 1.6-27.3; P = 0.008) ( Fig. 1 ). Fifteen patients with Ki-67 greater than 20% were identified, 10 (66.7%) of whom had N1 and 5 (33.3%) of whom had N0 (Fig. 2D ).
Preoperative Prediction of Nodal Metastases
The 2 preoperative variables associated with lymph node metastases (tumor location and tumor size) were analyzed for their ability to identify a group at low risk for nodal metastases. A probability plot for N stage greater than 0 versus tumor size for both tumors in the head and body tail of the pancreas was generated (Fig. 3 ). In the pancreatic head, even the smallest tumors had a probability that was unlikely to be less than 20% of having nodal metastasis (the lower bound of the CI is slightly below 20%). In the body-tail group, the smallest tumors had an estimated probability of nodal metastasis close to 20% (8.8% lower bound of 95% CI). Multivariate analysis did not identify an independent predictor of lymph node metastasis.
SURVIVAL

Disease-Free Survival
The association between lymph node status and DFS was analyzed using a Kaplan-Meier model (Fig. 4 ). Lymph node metastasis was found to be significantly associated with a decrease in DFS. The median of DFS was 4.5 years for patients with nodal metastasis compared with 14.6 years for patients without. The 5-and 10-year DFS was 86.8% and 70.8%, respectively, for N0 patients compared with 48.2% and 32.1%, respectively, for patients with N1 disease (log-rank <0.0001). Median DFS in patients with Ki-67 less than 2%, 2% to 20%, and greater than 20% was 11.7, more than 5.9, and 2.6 years, respectively (log-rank = 0.0004).
Overall Survival Lymph Node Status
Shorter OS was observed in patients with nodal metastases (N1), but the difference was not statistically significant. Five-and 10-year OS for patients with N1 disease were 77.1% and 55.4%, respectively, compared with 91.3% and 74.6% for patients with N0 disease (log-rank = 0.1).
Surgical Margin
Patients with positive surgical margins (R1 resections) were found to have shorter OS than patients with negative margins (Fig. 5 ). The median OS for patients with positive margins was 7.6 years compared with > 11.7 years for patient with negative margins (log-rank = 0.007). Five-year actuarial survival rates were 63.3% (95% CI, 27.4-85.1) for patients with positive surgical margins and 88.2% (95% CI, 76.2-93.4) for those with negative margins. 3 . A probability plot for N stage greater than 0 versus tumor size for both tumors in the head and bodytail of the pancreas was generated. The smallest tumors in the pancreatic head have a probability that is very unlikely to be less 20% of having node metastasis; the lower bound of the CI is slightly below 20%. In tumors located at the body-tail, the smallest tumors also have an estimated probability of node metastasis close to 20%, with 8.8% lower bound of 95% CI. 
Tumor Grade
There was a statistically significant association between longer OS and improvement in tumor differentiation as demonstrated by the 5-and 10-year survival rates for poorly differentiated (64.3% and 21.4%), moderately differentiated (96.0% and 56.1%), and welldifferentiated tumors (88.6% and 81.8%, log-rank = 0.017).
Ki-67 Index
Patients were stratified into 3 groups of Ki-67 percent less than 2, 2 to 20, and greater than 20, as previously described. 20, 21 Median OS for patients with Ki-67 greater than 20% was 7.1 years compared with greater than 8.5 years for those with Ki-67 index less than 2% (log-rank = 0.0004). Five-year survival for patients with Ki-67 greater than 20% was 56.9%, for Ki-67 between 2% and 20% was 88.1%, and for Ki-67 less than 2% was 90.5% (log-rank = 0.0004).
Multivariate Analysis
Multivariate analysis showed N1 status and Ki-67 greater than 20% are independently associated with DFS, P value of 0.0002 and 0.003, respectively. It also showed that positive surgical margin and Ki-67 greater than 20% are independently associated with OS, P value of 0.03 and 0.04, respectively.
Other Factors
In some studies, PNET associated with MEN-1 or functional tumors have been reported as having a better prognosis. 6, 22 Our data showed that neither of these 2 factors significantly affected OS or DFS. The log-rank tests of OS and DFS for patients with MEN-1 compared with others were 0.3 and 0.1 respectively. Eight patients with functional tumors were identified: of these, 5 were insulinomas and 3 were gastrinomas. The log-rank tests of OS and DFS for patients with functional compared with nonfunctional tumors were 0.2 and 0.1, respectively. MEN-1, functional tumors, ethnicity, sex, age at operation, and the presence of perineural infiltration were not found to affect OS and DFS.
DISCUSSION
Surgical resection is considered the mainstay of treatment with locoregional PNET and represents the only chance for cure. 7, 8 The optimal management for PNET is controversial as reported by National Comprehensive Cancer Network guidelines. 23 With increased utilization of cross-sectional imaging, clinicians are identifying many more patients with incidental PNET. Treatment options span the spectrum from observation to oncologic resection. Observation seems quite reasonable to consider for small, well-differentiated PNET given the often-indolent nature of the disease. This option is very sensible in the elderly patients and/or patients with significant comorbidities where the risks of surgery would outweigh the benefit of resection. At the other end of the spectrum is oncologic resection of the pancreas with regional lymphadenectomy. With increased technology, the surgical options continue to expand, and one can find several small series and case reports where local therapies, including enucleation, limited (central) pancreatectomy, and ablative procedures have been reported. 14, 16, 24 Historically, all series of surgical innovations for PNET demonstrate favorable short-term outcomes. However, given the indolent nature of many PNETs, it will take several decades to determine whether these local treatments have compromised long-term outcomes for patients.
In some studies, PNETs associated with MEN-1 or functional tumors have been reported as having a better prognosis. 6, 22 In this study, MEN-1 and functional status did not affect OS and DFS. Thus, they were included in the study. In our series, 98% of patients underwent resection inclusive of regional lymph nodes. Our institutional bias toward complete oncologic resection for PNET represents an advantage as the completeness of the data set exceeds that of previous reports.
We have separated the discussion to address 2 noteworthy questions. First, what is the clinical significance of positive lymph nodes? Second, which clinicopathologic factors might correlate with lymph node metastases? If we can better understand these 2 questions, we might be able to better select patients for observation, local therapies, or oncologic resection with regional lymphadenectomy.
In the literature, the importance of nodal metastasis in PNET remains controversial. 6, [10] [11] [12] For example, studies have concluded that nodal metastases are predictors of survival, 10, 11 whereas others showed no association. 6, 12 Our data showed that lymph node metastasis was associated with decrease in DFS (log-rank < 0.0001). Shorter OS was observed in patients with nodal metastasis, but the data were not statistically significant (log-rank = 0.1). We interpret these data as supportive of regional lymphadenectomy, because these yield important prognostic information about recurrence. It is also likely that with longer follow-up many patients who recurred may yet proceed to die of their disease and that with more time, OS survival will also become statistically significant.
This study found that positive surgical margin was associated with worse OS (log-rank = 0.007). Similar findings were reported by others. 22, 25 A positive margin can be left behind because one does a smaller operation for a similar tumor or because a tumor is somehow more aggressive and, therefore, a clear margin is more difficult to achieve. If we entertain that tumor left behind may have a negative impact, these data would also support an oncologic resection, as it would be more likely to achieve a negative surgical margin. By extension, it could be argued that if leaving tumor behind at a margin matters, it should also matter if it is left behind in lymph nodes, but this conclusion is more speculative.
Tumor size and location were identified as predictors of lymph nodes metastasis. We elected to jointly analyze these because they are reliably available to a surgeon preoperatively. Tsutsumi, K et al 26 reported increased prevalence of lymph node metastasis in patients with gastrinoma and nongastrinoma, with tumor size of 1.5 cm or larger. They also found that 2 (8%) patients with gastrinoma out of 26 patients with tumor smaller than 1.5 cm had nodal metastasis. 26 In contrast, Parekh et al 9 reported that there was no difference in tumor size for patients with and without nodal metastasis, as 31% of patients with tumor smaller than 3 cm had nodal metastasis. Haynes et al 27 reported an association between tumor size larger than 2 cm and metastasis or progression of the disease; however, 8% of the patients with smaller tumors developed metastasis. This study showed increased probability of nodal metastasis when the tumor size was larger than 1.5 cm (P = 0.002). However, 2 of 17 patients (12%) with a tumor size of 1 cm or smaller had nodal metastasis. We also found that tumors in the head of the pancreas compared with the body-tail were more likely to be associated with nodal metastasis (P = 0.007). However, there were 17 of 47 patients (26.6%) who had their tumors in the body-tail and had lymph node metastasis. The probability plot of nodal metastasis considering size and location revealed that even the smallest tumors in the body-tail have an estimated probability of node metastasis close to 20% with 8.8% lower bound of 95% CI (Fig. 3) . Tumor size and location together could not reliably predict a group of patients at low risk for nodal metastases.
Several authors have suggested surgical approaches on the basis of tumor size. [28] [29] [30] [31] Enucleation of PNET is becoming more common as minimally invasive techniques are more widely adapted. Yeo et al 28 considered enucleation as the procedure of choice for tumors smaller than 2 cm that are not close to the main pancreatic duct. Fernandez-Cruz et al 29 suggested enucleation for nonfunctional tumor if the size of the tumor is smaller than 3 cm, but they recommended lymph node sampling with frozen section and to proceed with enucleation and node dissection if malignancy is confirmed. Sarmiento et al 30 suggested pancreaticoduodenectomy for tumors in the head in presence of malignancy or technical contraindication to enucleation. Bettini et al 31 reported strong association between tumor size and malignancy in nonfunctional PNET. They suggested nonoperative treatment of tumors sized 2 cm or smaller. Reviews from the literature demonstrated that even small tumors smaller than 1.5 cm and smaller than 3 cm metastasize with a rate of 8% to 31%, respectively. 9, 26 These results are consistent with our finding of 12% metastatic rate for tumors of 1 cm or smaller. Even if we accept that oncologic resection with regional lymphadenectomy is associated with an increased risk of death compared with enucleation, it is unclear what the percentage of acceptable missed metastases would be. If leaving metastases behind does not matter, it may be correct that the primary tumor should be left alone. The authors interpret these data to suggest that if you are going to the operating room because the tumor has risk and your mortality rate for oncologic resection is acceptably low, then oncologic resection should be the standard operation for the majority of patients.
Additional predictors of nodal metastasis were LVI and Ki-67 index greater than 20%. These predictors are less likely to help in planning the type of surgery because they are not reliably available preoperatively. Ki-67 proliferative index can certainly be obtained on biopsy, but it was reported that biopsy is not always reliable because tumors can be quite heterogeneous. 32 This additional procedure has risks and the 2 patients with tumor size of 1 cm or smaller and nodal metastasis had Ki-67 less than 20%. Further study is warranted as the combination of Ki-67% and tumor size might ultimately help in combination with other factors to predict a low-risk tumor that should be observed.
The retrospective nature of the data collection and the fact that this is a single-institute experience are well-appreciated limitations of this study. The patients for this study were selected from a surgical database and patients selected for observation of their tumors were not included. In determining the optimal treatment of an indolent disease, it is important to take into consideration the complication rates for the planned procedure and the potential longevity of the patient. The complication rates reported for these patients were lower than expected when compared with our own previously reported rates 33, 34 and the literature. [35] [36] [37] [38] However, these were obtained retrospectively and span 2 decades. Therefore, it is highly likely that this represents an incomplete picture of the complications for oncologic resection for neuroendocrine tumor. The pancreas is often soft and complications are thought to be higher in this situation. We have maintained a prospective database of complications for patients undergoing a Whipple for the last 2 years. During this time span, we performed 185 Whipple procedures of which 23 were performed for PNET. In this prospective cohort, there was a 1.5% mortality rate, with no deaths in the PNET group. There was a 17% pancreatic leak rate that was not statistically different from the PNET group at 26%. The great majority of leaks were grade 1, but oncologic resection clearly has associate risks. We are in support of further collaborative study to better understand the optimal management of PNET.
CONCLUSIONS
In summary, we believe that oncologic resection with regional lymphadenectomy should be offered to the majority of patients undergoing surgery for PNETs. Patients with nodal metastasis demonstrated worse prognosis, and this information adds prognostic value for both patients and treating physicians. Furthermore, lymph node status may be critically important to stratify patients for future trials investigating adjuvant treatment. Currently, we lack accurate preoperative methods to predict which tumors will be well behaved and which will progress to regional or distant metastasis. There was a decrease in OS with positive surgical margin, and this is more likely to happen with enucleation than with anatomic resection. The potential for surgical complications needs to be considered for each patient; however, we interpret the continual improvements in mortality and morbidity for oncologic resection in high-volume centers [35] [36] [37] [38] as supportive of the aggressive approach. We also recommend long periods of surveillance (≥10 years) and additional vigilance for patients with nodal involvement, LVI, Ki-67 greater than 20%, poorly differentiated tumors, and positive surgical margins.
